Zipalertinib Plus Chemotherapy Meets Primary Pfs Endpoint In Planned Interim Analysis Of Phase 3 Rezilient3 Trial
13/08/2026 24:32
BRIEF-Otsuka Holdings Co., Ltd. - Zipalertinib Plus Chemotherapy Meets Primary Pfs Endpoint In Planned Interim Analysis Of Phase 3 Rezilient3 Trial Aug 13 (Reuters) - Otsuka Holdings Co., Ltd. 4578.T:
OTSUKA HOLDINGS CO., LTD.: ZIPALERTINIB PLUS CHEMOTHERAPY MEETS PRIMARY PFS ENDPOINT IN PLANNED INTERIM ANALYSIS OF PHASE 3 REZILIENT3 TRIAL
Source text: ID:nTStl7ea4e
Further company coverage: 4578.T
(Reporting by Tokyo Newsroom)
((+81345201189;))